Gregory M Weinhoff
CIK 1400975 · Chief Business Officer · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
2
Total Filings
60
Lifetime Open-Market Net
-$6.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Chief Business Officer | 0 | $40.50 | $0 | -$5.64M | 36 | 2026-06-24 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 1,928,612 | $14.49 | $27.95M | -$850.0K | 3 | 2008-08-18 |
Recent Filings · Page 4 of 6
60 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-25 | — | Notice (144) | −16,619 | -$262.6K | EDGAR |
| 2024-09-12 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | — | -$334.8K | EDGAR |
| 2024-09-10 | — | Notice (144) | −30,000 | -$510.0K | EDGAR |
| 2024-09-09 | — | Notice (144) | −25,000 | -$375.0K | EDGAR |
| 2024-09-09 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | — | -$229.0K | EDGAR |
| 2024-08-23 | — | Notice (144) | −17,802 | -$218.8K | EDGAR |
| 2024-08-23 | Centessa Pharmaceuticals plc (CNTA) Delisted | Sell (S) | −30,000 | -$367.2K | EDGAR |
| 2024-08-22 | — | Notice (144) | −12,198 | -$149.3K | EDGAR |
| 2024-07-02 | Centessa Pharmaceuticals plc (CNTA) Delisted | Tax (F) | −11,742 | -$106.0K | EDGAR |
| 2024-04-02 | Centessa Pharmaceuticals plc (CNTA) Delisted | Tax (F) | −11,742 | -$132.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.